Pharma Leader Series: Top 30 Ophthalmic Drug Manufacturers 2019-2029

1. Report Overview 1.1 Global Ophthalmic Drugs Market Overview 1.2 Global Ophthalmic Drugs Market Segmentation 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Key Questions Answered by This Analytical Report 1.6 Who is This Report For? 1.7 Methodology 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Visiongain Reports 1.10 About Visiongain 2. Introduction to Ophthalmic Drugs 2.1. The Pharmaceutical Industry: Very Brief Overview 2.2. The Global Burden of Eye Disease 2.3. Ophthalmic Drugs: Market Segmentation 2.4 Glaucoma: the 'Silent Thief of Sight' 2.4.1 A Classification of Glaucoma 2.4.1.1 Primary Open-Angle Glaucoma 2.4.1.2 Acute Angle-Closure Glaucoma 2.4.1.3 Congenital Glaucoma 2.4.1.4 Secondary Glaucoma 2.4.1.5 Normal-Tension Glaucoma 2.4.1.6 Ocular Hypertension 2.4.2 Risk Factors for Glaucoma 2.4.3 Diagnosis of Glaucoma 2.4.4 Drug Treatment of Glaucoma 2.4.5 Laser Treatment and Surgery for Glaucoma 2.5 Treatment of AMD 2.6 Diabetic Retinopathy (DR) 2.6.1 Diagnosis of Diabetic Retinopathy 2.6.2 Treatment of Diabetic Retinopathy 2.7 Ocular Allergy and Allergic Conjunctivitis 2.7.1 Diagnosis of Ocular Allergy 2.7.2 Treatment of Ocular Allergy 2.8 Ocular Inflammatory Disease 2.8.1 Treatment of Ocular Inflammatory Disease 2.9 Eye Infections 2.9.1 Treatment of Eye Infections 2.10 Dry Eye Syndrome 2.10.1 Treatment of Dry Eye Syndrome 2.11 Phases of Clinical Trials 3. Ophthalmic Drugs Market, 2019-2029 3.1 Global Ophthalmic Drugs: Market Overview 3.1.1 The World Ophthalmic Drugs Market in 2018 3.2 Global Ophthalmic Drugs: Market Forecast 2019-2029 3.3. Leading Ophthalmic Drugs 3.4 Leading Companies in the Global Ophthalmic Drugs Market 3.4.1 Top 30 Ophthalmic Drug Manufacturers 3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2019-2029 3.5.1 Retinal Disorders Drugs Market: Sales Forecast 2019-2029 3.5.2 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2019-2029 3.5.3 Glaucoma Drugs Market: Sales Forecast 2019-2029 3.5.4 Dry Eye Drugs Market: Sales Forecast 2019-2029 3.5.5 Other Ophthalmic Drugs Market: Sales Forecast 2019-2029 3.6 How Will Market Shares Change to 2029? 3.7 World Ophthalmic Drugs Market: Drivers and Restraints 2019-2029 3.7.1 World Ophthalmic Drugs Market: Analysis of Drivers 3.7.2 World Ophthalmic Drugs Market: Analysis of Restraints 4. Leading US Ophthalmic Drugs Manufacturers 2019-2029 4.1 Allergan: Overview 4.1.1 Allergan: Ophthalmic Product Portfolio 4.1.1.1 Restasis 4.1.1.2 Restasis: Sales Forecast 2019-2029 4.1.1.3 Lumigan and Ganfort: Marketed in Over 67 Countries 4.1.1.4 Lumigan and Ganfort: Sales Forecast 2019-2029 4.1.1.5 Refresh Brand Products: The Range 4.1.1.6 Alphagan/Alphagan P and Combigan: Extended Lifecycle 4.1.1.7 Alphagan/Alphagan P and Combigan: Sales Forecast 2019-2029 4.1.1.8 Acular: New Forms Receiving FDA Approvals 4.1.1.9 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Edema 4.1.2 Allergan: Late Stage Ophthalmic Product Pipeline 4.1.3 Allergan: Ophthalmic Revenue Forecast 2019-2029 4.1.3.1 Allergan: Ophthalmic Drugs Market Share Forecast 2019-2029 4.1.4 Allergan: SWOT Analysis 4.2 Pfizer Overview 4.2.1 Pfizer: Ophthalmic Product Portfolio 4.2.1.1 Xalatan/Xalacom: First Ophthalmic Blockbuster 4.2.1.2 Xalatan/Xalacom: Sales Forecast 2019-2029 4.2.2 Pfizer: Ophthalmic Product Pipeline 4.2.3 Pfizer: Revenue Forecast 2019-2029 4.2.3.1 Pfizer: Ophthalmic Drugs Market Share Forecast 2019-2029 4.2.4 Pfizer: SWOT Analysis 4.3 Regeneron Overview 4.3.1 Regeneron: Ophthalmic Product Portfolio 4.3.1.1 Eylea: Superior Clinical Outcomes than Lucentis and Avastin? 4.3.1.2 Eylea: US Sales Forecast 2019-2029 4.3.2 Regeneron: Ophthalmic Product Pipeline 4.3.3 Regeneron: Revenue Forecast 2019-2029 4.3.3.1 Regeneron: Ophthalmic Drugs Market Share Forecast 2019-2029 4.3.4 FDA Approves Zaltrap (aflibercept) 4.3.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements 4.3.6 Regeneron: SWOT Analysis 4.4 Akorn Overview 4.4.1 Akorn: Ophthalmic Product Portfolio 4.4.1.1 AzaSite: AzaSite Plus and AzaSite Xtra Set to Drive AzaSite Sales 4.4.1.2 Cosopt/Cosopt PF: Acquired from Merck 4.4.2 Akorn: Revenue Forecast 2019-2029 4.4.2.1 Akorn: Ophthalmic Drugs Market Share Forecast 2019-2029 4.4.3 Akorn: SWOT Analysis 5. Leading European Ophthalmic Drug Manufacturers, 2019-2029 5.1 Bayer Overview 5.1.1 Bayer: Ophthalmic Product Pipeline 5.1.2 Eylea: non-US Sales Forecast 2019-2029 5.1.3 Bayer: Revenue Forecast 2019-2029 5.1.3.1 Bayer: Ophthalmic Drugs Market Share Forecast 2019-2029 5.2 Novartis (including Alcon) Overview 5.2.1 Novartis: Ophthalmic Product Portfolio 5.2.1.1 Lucentis: Still a Leading Drug in AMD 5.2.1.2 Lucentis: Non-US Sales Forecast 2019-2029 5.2.1.3 Travatan/Travatan Z and DuoTrav: DuoTrav Awaiting US Approval 5.2.1.4 Travatan/Travatan Z and DuoTrav: Sales Forecast 2018- 2029 5.2.1.5 Vigamox: Competes with Alcon's Moxeza 5.2.1.6 Vigamox: Sales Forecast 2019- 2029 5.2.1.7 Azopt: Marketed in Major Markets 5.2.1.8 Azopt: Sales Forecast 2019 - 2029 5.2.1.9 Jetrea: Sales Revenues Fall Short 5.2.2 Novartis: Ophthalmic Product Pipeline 5.2.2.1 Finafloxacin (MerLion Pharmaceuticals/Novartis) 5.2.2.2 AKB-9778 (Aerpio Therapeutics) 5.2.3 Novartis: Revenue Forecast 2019 - 2029 5.2.3.1 Novartis: Ophthalmic Drugs Market Share Forecast 2019-2029 5.2.4 Novartis: SWOT Analysis 5.3 Roche Overview 5.3.1 Roche: Ophthalmic Product Portfolio 5.3.1.1 Lucentis: US Sales Forecast 2019-2029 5.3.1.2 Avastin: Off-Label Use for Wet AMD Cannibalising Lucentis Sales 5.3.1.3 Avastin: Sales Forecast 2019 - 2029 5.3.2 Roche: Ophthalmic Product Pipeline 5.3.2.1 Lampalizumab (RG7417) 5.3.3 Roche: Revenue Forecast 2019-2029 5.3.3.1 Roche: Ophthalmic Drugs Market Share Forecast 2019-2029 5.3.4 Roche: SWOT Analysis 6. Leading Asia-Pacific Ophthalmic Drugs Manufacturers 2019-2029 6.1 Santen Overview 6.1.1 Santen: Ophthalmic Product Portfolio 6.1.1.1 Eylea: Japan Sales Forecast 2019-2029 6.1.1.2 Hyalein 6.1.1.3 Hyalein: Sales Forecast 2019-2029 6.1.1.4 Cosopt: Non-US Sales Forecast 2019-2029 6.1.1.5 Tapros/Taflotan: Sales Forecast 2019-2029 6.1.1.6 Diquas: Sales Forecast 2019-2029 6.1.1.7 Cravit: Higher Concentration Showing Significant Efficacy 6.1.1.8 Cravit: Sales Forecast 2019-2029 6.1.1.9 Alesion: Sales Forecast 2019-2029 6.1.2 Santen: Ophthalmic Product Pipeline 6.1.3 Santen: Revenue Forecast 2019-2029 6.1.3.1 Santen: Ophthalmic Drugs Market Share Forecast 2019-2029 6.1.4 Santen: SWOT Analysis 6.2 Senju Overview 6.1.1 Senju: Ophthalmic Product Portfolio 6.2.2 Senju: Ophthalmic Product Pipeline 6.2.2.1 Y-39983 (SNJ-1656) 6.2.2.2 Difluprednate (SJE-2079) 6.2.3 Senju: Revenue Forecast 2019-2029 6.2.3.1 Santen: Ophthalmic Drugs Market Share Forecast 2019-2029 6.2.4 Senju: SWOT Analysis 6.3 Valeant Overview 6.3.1 Valeant: Ophthalmic Product Portfolio 6.3.1.1 Lotemax: New Formulation Launch Expected in 2016 6.3.1.2 Lotemax: Sales Forecast 2019-2029 6.3.2 Valeant: Ophthalmic Product Pipeline 6.3.2.1 Vesneo (Latanoprostene Bunod) 6.3.2.2 Brimonidine tartarate 0.0025% for Eye Whitening (Valeant) 6.3.3 Valeant: Revenue Forecast 2019-2029 6.3.3.1 Valeant: Ophthalmic Drugs Market Share Forecast 2019-2029 6.3.4 Valeant: SWOT Analysis 6.3.4.1 Valeant's Acquisition of Bausch and Lomb: Aggressive Expansion? 6.3.4.2 Valeant: Difficult End to 2015 Puts Company Future in Doubt 7. Emerging Ophthalmic Drug Manufacturers in 2018 7.1 Acucela 7.2 Aerie Pharmaceuticals 7.3 Aerpio Therapeutics: Developing AKB-9778 7.4 Alimera Sciences 7.4.1 Iluvien: Increasing Geographical Reach and Increasing Sales 7.4.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD 7.5 Amakem 7.6 Ampio Pharmaceuticals 7.7 Chengdu Kanghong Pharmaceutical 7.8 Eleven Biotherapeutics 7.9 EyeGate Pharmaceuticals 7.10 Gene Signal 7.10.1 Aganirsen: Preventing Corneal Graft Rejection 7.11 Icon Bioscience 7.12 MacuCLEAR 7.12.1 MC-1101: a Potential Therapy for Dry AMD 7.13 Neurotech 7.14 Omeros 7.15 OphthaliX (Can-Fite BioPharma) 7.16 Ophthotech 7.16.1 Fovista: Potential Game-Changer in AMD 7.16.2 Fovista: Significant Improvement on Lucentis in Phase II Trials 7.16.3 Zimura: Complement C5 Inhibitor 7.17 Otsuka Pharmaceutical 7.18 pSivida Corp. 7.19 RXi Pharmaceuticals: Will Bevasiranib Resume Development? 7.20 Shire 7.20.1 Lifitegrast (SHP606) for Dry Eye 7.20.2 Premiplex (SHP607): Preventing Retinopathy of Prematurity 7.21 ThromboGenics 7.21.1 Jetrea (ocriplasmin) 7.21.2 ThromboGgenics: Leading Diabetic Eye Disease Pipeline 7.22 Sun Pharmaceutical Industries Ltd. (XELPROS) 8. Qualitative Analysis of the Ophthalmic Drugs Market 2019-2029 8.1 Porter's Five Forces Analysis of the Ophthalmic Drugs Market 8.1.1 Rivalry Among Competitors [Medium] 8.1.2 Threat of New Entrants [Low] 8.1.3 Power of Suppliers [Low] 8.1.4 Power of Buyers [Medium] 8.1.5 Threat of Substitutes [Medium] 9. Conclusions 9.1 Ophthalmic Pharmaceuticals: A Growing Niche Market 9.2 The World Ophthalmic Drugs Market in 2019 9.2.1 Leading Ophthalmic Drugs Market Segments 9.2.2 Leading Ophthalmic Drugs 9.2.3 Leading Ophthalmic Drug Companies 9.3 World Ophthalmic Drugs Market Forecast 2019-2029 9.4 The Future of the Ophthalmic Drugs Market? 9.4.1 Increasing Revenue Concentration among Specialist Companies 9.4.2 The Rise of Generics 9.4.3 Small Companies Can Have a Big Impact 9.4.4 What Will Succeed in the Ophthalmic Drugs Market? Appendices Associated Visiongain Reports Visiongain Report Sales Order Form About Visiongain Visiongain Report Evaluation Form List of Tables Table 2.1 ICD-10 Classification of Visual Impairment Table 2.2 Drug Treatments for Glaucoma, 2018 Table 2.3 Drug Treatments for AMD, 2018 Table 2.4 Drug Treatments for Ocular Allergy, 2018 Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2018 Table 2.6 Selected Drug Treatments for Eye Infections, 2018 Table 2.7 Clinical Trial Phases Table 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2018 and 2019 Table 3.2 Global Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029 Table 3.3 Top 10 Ophthalmic Drugs: Revenue ($m), Market Share (%), Rank, Active Ingredient and Manufacturer, 2018 Table 3.4 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Table 3.5 Top 30 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Leading Pipeline Products, 2018 Table 3.6 Global Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029 Table 3.7 Retinal Disorders Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029 Table 3.8 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029 Table 3.9 Glaucoma Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029 Table 3.10 Dry Eye Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029 Table 3.11 Other Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029 Table 3.12 Market Shares (%) of the Ophthalmic Drugs Market by Segment, 2018, 2023 and 2029 Table 4.1 Allergan: Overview, 2019 Table 4.2 Top 10 Ophthalmic Drugs: Revenue ($m), Market Share (%), Rank, Active Ingredient and Manufacturer, 2018 Table 4.3 Allergan: Restasis Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 4.4 Allergan: Lumigan and Ganfort Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 4.5 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 4.6 Allergan: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 4.7 Allergan: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 4.8 Allergan: Ophthalmic Drugs Market SWOT Analysis, 2019-2029 Table 4.9 Pfizer: Overview, 2019 Table 4.10 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 4.11 Pfizer: Ophthalmic Drugs Revenue($m), AGR (%) and CAGR (%), 2019-2029 Table 4.12 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 4.13 Pfizer: Ophthalmic Drugs Market SWOT Analysis, 2019-2029 Table 4.14 Regeneron: Overview, 2019 Table 4.15 Regeneron: Eylea Revenue ($m), AGR (%) and CAGR (%) 2019-2029 Table 4.16 Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 4.17 Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 4.18 Regeneron: Ophthalmic Drugs Market SWOT Analysis, 2019-2029 Table 4.19 Akorn: Overview, 2019 Table 4.20 Akorn: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 4.21 Akorn: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 4.22 Akorn: Ophthalmic Drugs Market SWOT Analysis, 2019-2029 Table 5.1 Bayer: Overview, 2019 Table 5.2 Bayer: Eylea Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 5.3 Bayer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 5.4 Bayer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 5.5 Novartis: Overview, 2019 Table 5.6 Novartis: Lucentis Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 5.7 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 5.8 Novartis: Vigamox Revenue ($m), AGR (%) and CAGR(%), 2019-2029 Table 5.9 Novartis: Azopt Revenue ($m), AGR (%) and CAGR(%), 2019-2029 Table 5.10 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019 - 2029 Table 5.11 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 5.12 Novartis: Ophthalmic Drugs Market SWOT Analysis, 2019 - 2029 Table 5.13 Roche: Overview, 2019 Table 5.14 Roche: Lucentis Revenue ($m), AGR (%) and CAGR (%) 2019- 2029 Table 5.15 Roche: Avastin Ophthalmic Revenue ($m), AGR (%) and CAGR (%), 2019 - 2029 Table 5.16 Roche: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 5.17 Roche: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 5.18 Roche: Ophthalmic Drugs Market SWOT Analysis, 2019- 2029 Table 6.1 Santen: Overview, 2019 Table 6.2 Santen: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Date, Region, 2019 Table 6.3 Santen: Eylea Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 6.4 Santen: Hyalein Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 6.5 Santen: Cosopt Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 6.6 Santen: Tapros/Taflotan Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 6.7 Santen: Diquas Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 6.8 Santen: Cravit Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 6.9 Santen: Alesion Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 6.10 Santen: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 6.11 Santen: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 6.12 Santen: Ophthalmic Drugs Market SWOT Analysis, 2019-2029 Table 6.13 Senju: Overview, 2019 Table 6.14 Senju: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Year, 2019 Table 6.15 Senju: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 6.16 Senju: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 6.17 Senju: Ophthalmic Drugs Market SWOT Analysis, 2019-2029 Table 6.18 Valeant: Overview, 2019 Table 6.19 Valeant: Lotemax Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 6.20 Valeant: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029 Table 6.21 Valeant: Ophthalmic Drugs Market Share (%), Revenue ($m), 2019-2029 Table 6.22 Valeant: Ophthalmic Drugs Market SWOT Analysis, 2019-2029 Table 7.1 Otsuka Pharmaceutical: Overview of Ophthalmic Drug Pipelines, Drug Type, Indication, Country Table 9.1 Leading Ophthalmic Drugs Manufacturers: Revenues ($m), Market Share (%). 2018 List of Figures Figure 1.1 Global Causes of Visual Impairment (% of Cases), 2018 Figure 1.2 World 65+ Population Forecast: Size (millions), CAGR (%), by National Market, 2015 and 2026 Figure 1.3 Global Ophthalmic Drugs Market Segmentation Overview, 2019 Figure 2.1 Estimated Global Blindness and Visual Impairment (% of people), 2018 Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2018 Figure 2.3 Global Causes of Visual Impairment (% of Cases) Figure 2.4 Global Causes of Blindness (% of cases) Figure 2.5 Classification of Glaucoma, 2018 Figure 3.1 The Global Ophthalmic Drugs Market Forecast by Sector, 2018 and 2019 Figure 3.2 The Global Ophthalmic Drugs Market Forecast by Sector, 2018 and 2019 Figure 3.3 Global Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029 Figure 3.4 Top 9 Ophthalmic Drugs: Revenues ($m), 2018 Figure 3.5 Top 9 Ophthalmic Drugs: Market Share (%), 2018 Figure 3.6 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs: Revenues ($m), 2018 Figure 3.7 Top 10 Ophthalmic Drug Manufacturers: Market Share (%), 2018 Figure 3.8 Retinal Disorders Drugs Market Forecast: Revenue ($m), 2019-2029 Figure 3.9 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), 2019-2029 Figure 3.10 Glaucoma Drugs Market Forecast: Revenue ($m), 2019-2029 Figure 3.11 Dry Eye Drugs Market Forecast: Revenue ($m), 2019-2029 Figure 3.12 Other Ophthalmic Drugs Market Forecast: Revenue ($m), 2019-2029 Figure 3.13 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2018 Figure 3.14 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2023 Figure 3.15 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2029 Figure 3.16 Ophthalmic Drugs Market Drivers & Restraints 2019-2029 Figure 4.1 Allergan: Restasis Revenue ($m) and AGR (%), 2019-2029 Figure 4.2 Allergan: Lumigan and Ganfort Revenue ($m) and AGR (%), 2019-2029 Figure 4.3 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m) and AGR (%), 2019-2029 Figure 4.4 Allergan: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 4.5 Allergan: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 4.6 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), 2019-2029 Figure 4.7 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%), 2019-2029 Figure 4.8 Pfizer: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 4.9 Regeneron: Eylea Revenue ($m) and AGR (%), 2019-2029 Figure 4.10 Regeneron: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 4.11 Regeneron: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 4.12 Akorn: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 4.13 Akorn: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 5.1 Bayer: Eylea Revenue ($m) and AGR (%), 2019- 2029 Figure 5.2 Bayer: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019- 2029 Figure 5.3 Bayer: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 5.4 Novartis: Lucentis Revenue ($m), AGR (%), 2019- 2029 Figure 5.5 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m) and AGR (%), 2019-2029 Figure 5.6 Novartis: Vigamox Revenue ($m) and AGR (%), 2019- 2029 Figure 5.7 Novartis: Azopt Revenue ($m) and AGR (%), 2019- 2029 Figure 5.8 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%), 2019- 2029 Figure 5.9 Novartis: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 5.10 Roche: Lucentis Revenue ($m) and AGR (%), 2019- 2029 Figure 5.11 Roche: Avastin Ophthalmic Revenue ($m) and AGR(%), 2019-2029 Figure 5.12 Roche: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 5.13 Roche: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 6.1 Santen: Ophthalmic Drugs Revenue ($m) by Segment, FY 2018 Figure 6.2 Santen: Ophthalmic Drugs Revenue ($m) by Segment, FY 2018 Figure 6.3 Santen: Eylea Revenue ($m) and AGR (%), 2019-2029 Figure 6.4 Santen: Hyalein Revenue ($m) and AGR (%), 2019-2029 Figure 6.5 Santen: Cosopt Revenue ($m) and AGR (%), 2019-2029 Figure 6.6 Santen: Tapros/Taflotan Revenue ($m) and AGR (%), 2019-2029 Figure 6.7 Santen: Diquas Revenue ($m) and AGR (%), 2019-2029 Figure 6.8 Santen: Cravit Revenue ($m) and AGR (%), 2019-2029 Figure 6.9 Santen: Alesion Revenue ($m) and AGR (%), 2019-2029 Figure 6.10 Santen: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 6.11 Santen: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 6.12 Senju: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 6.13 Senju: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 6.14 Valeant: Lotemax Revenue ($m) and AGR (%), 2019-2029 Figure 6.15 Valeant: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029 Figure 6.16 Valeant: Ophthalmic Drugs Market Share (%), 2019-2029 Figure 7.1 Gene Signal: Ophthalmic Drug Pipeline Progress Figure 7.2 Ophthotech: Ophthalmic Drug Pipeline Progress Figure 7.3 Otsuka Pharmaceutical: Ophthalmic Drug Pipeline Progress Figure 7.4 Shire: Ophthalmic Drug Pipeline Progress Figure 8.1 Porter's Five Force Analysis Figure 9.1 The Global Ophthalmic Drugs Market Forecast by Sector, 2018 and 2019